Endari® Receives Kuwaiti Marketing Authorization
TORRANCE Calif., Dec. 7, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received Registration Approval from the Pharmaceutical and Herbal Medicines Registration and Control Administration (Drug and Food Control) of the Kuwaiti Ministry of Health granting marketing authorization for the commercial distribution and sale of Endari® in the country. Kuwait is the latest Gulf Cooperation Council (GCC) country to grant full marketing approval for Endari® following approvals in the United Arab Emirates and the State of Qatar earlier this year.
- Kuwait is the latest Gulf Cooperation Council (GCC) country to grant full marketing approval for Endari following approvals in the United Arab Emirates and the State of Qatar earlier this year.
- Endari is approved in the U.S. and elsewhere to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
- Endari is available on an early access basis in Bahrain and the Kingdom of Saudi Arabia pending official notice of action on Emmaus's marketing authorization applications in those countries.
- Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, commented, "We continue to see progress in our mission to make Endari available to the many sickle cell patients in the GCC countries and are grateful to the Kuwaiti officials for this latest marketing approval."